窦文朝,彭瑜,张钲

• 1:兰州大学第一临床医学院
• 2:兰州大学第一医院心脏中心
• 3:甘肃省心血管病临床医学研究中心

摘要(Abstract)：

经皮冠状动脉介入治疗（PCI）是当今冠状动脉疾病（CHD）的主要治疗方法。支架内再狭窄（ISR）的特征是支架内进行性管腔狭窄，这与PCI对于血管机械损伤引起的血管炎症、血小板活化、血管平滑肌细胞（VSMC）增殖和迁移以及细胞外基质重塑等相关。内皮细胞生长能愈合被支架损坏的血管内层，并防止血栓形成，而药物洗脱支架（DES）置入会在抑制VSMC增殖的同时，抑制靶病变处所有细胞的生长，这一问题亟待解决。目前，有研究表明一些围绕非编码RNA及相关的表观遗传通路开发的药物通过支架递送能够靶向抑制VSMC增殖，而不影响血管内膜再内皮化，促进血管内膜愈合。因此，本综述探讨了非编码RNA药物支架开发及相关临床试验的研究进展，以确定其在解决DES临床应用带来的相关问题的可行性。

关键词(KeyWords)： 经皮冠状动脉介入治疗;支架内再狭窄;非编码RNA药物支架;血管平滑肌细胞;内皮细胞;血栓形成

Abstract:

Keywords:

基金项目(Foundation):

作者(Author): 窦文朝,彭瑜,张钲

参考文献(References)：

• [1]国家卫生健康委员会.中国卫生健康统计年鉴2021[M].北京:中国协和医科大学出版社,2021.
• [2]中国心血管健康与疾病报告编写组.《中国心血管健康与疾病报告2022》概要[J].中国介入心脏病学杂志,2023,31(7):485-508.DOI:10.3969/j.issn.1004-8812.2023.07.002.
• [3]Gao JW,He WB,Xie CM,et al.Aldosterone enhances high phosphate-induced vascular calcification through inhibition of AMPK-mediated autophagy[J].J Cell Mol Med,2020,24(23):13648-13659.DOI:10.1111/jcmm.15813.
• [4]赵静雯,于海奕,张永珍,等.环状RNA circDYSF在不同类型冠心病患者外周血中的表达及临床价值探讨[J].中国介入心脏病学杂志,2022,30(11):801-807.DOI:10.39 69/j.iss n.1004-8812.2022.11.001.
• [5]郝伟,赵晨,胡思宁,等.冠状动脉药物洗脱支架内再狭窄的最新研究进展[J].中国介入心脏病学杂志,2023,31(1):63-68.DOI:10.3969/j.issn.1004-8812.2023.01.010.
• [6]韩燕,袁晓航,高磊.光学相干断层成像指导冠状动脉支架内再狭窄介入治疗进展[J].中国介入心脏病学杂志,2023,31(5):356-361.DOI:10.3969/j.issn.1004-8812.2023.05.006.
• [7] Kamiya A,Togawa T.Adaptive regulation of wall shear stress to flow change in the canine carotid artery[J].Am J Physiol,1980,239(1):H14-H21.DOI:10.1152/ajpheart.1980.23 9.1.H14.
• [8]Park SJ,Kang SJ,Virmani R,et al.In-stent neoatherosclerosis:a final common pathway of late stent failure[J].J Am Coll Cardiol,2012,59(23):2051-2057.DOI:10.1016/j.jacc.2011.10.909.
• [9]Pons D,de Vries FR,van den Elsen PJ,et al.Epigenetic histone acetylation modifiers in vascular remodelling:new targets for therapy in cardiovascular disease[J].Eur Heart J,2009,30(3):266-277.DOI:10.1093/eurheartj/ehn603.
• [10] Yang X,Yang Y,Guo J,et al.Targeting the epigenome in in-stent restenosis:from mechanisms to therapy[J].Mol Ther Nucleic Acids,2021,23:1136-1160.DOI:10.1016/j.omtn.20 21.01.024.
• [11]Pang Y,Mao C,Liu S.Encoding activities of non-coding RNAs[J].Theranostics,2018,8(9):2496-2507.DOI:10.7150/thno.24677.
• [12]Zhang J,Liu L,Xu T,et al.miRspongeR:an R/Bioconductor package for the identification and analysis of miRNA sponge interaction networks and modules[J].BMC Bioinformatics,2019,20(1):235.DOI:10.1186/s12859-019-2861-y.
• [13] Kopp F,Mendell JT.Functional classification and experimental dissection of long noncoding RNAs[J].Cell,2018,172(3):393-407.DOI:10.1016/j.cell.2018.01.011.
• [14]Yang F,Chen Q,He S,et al.miR-22 is a novel mediator of vascular smooth muscle cell phenotypic modulation and neointima formation[J].Circulation,2018,137(17):1824-1841.DOI:10.1161/CIRCULATIONAHA.117.027799.
• [15]Lee J,Heo J,Kang H.miR-92b-3p-TSC1 axis is critical for mTOR signaling-mediated vascular smooth muscle cell proliferation induced by hypoxia[J].Cell Death Differ,2019,26(9):1782-1795.DOI:10.1038/s41418-018-0243-z.
• [16]Zeng Z,Xia L,Fan X,et al.Platelet-derived miR-223 promotes a phenotypic switch in arterial injury repair[J].J Clin Invest,2019,129(3):1372-1386.DOI:10.1172/JCI124 508.
• [17]Li P,Zhu N,Yi B,et al.MicroRNA-663 regulates human vascular smooth muscle cell phenotypic switch and vascular neointimal formation[J].Circ Res,2013,113(10):1117-1127.DOI:10.1161/CIRCRESAHA.113.301306.
• [18]Efovi D,Xiao Q.Noncoding RNAs in vascular cell biologyand restenosis[J].Biology(Basel),2022,12(1):24.DOI:10.3390/biology 12010024.
• [19]Kielbowski K,Zychowska J,Bakinowska E,et al.Non-coding RNA involved in the pathogen esis of atherosclerosis—a narrative review[J].Diagnostics(Basel),2024,14(17):1981.DOI:10.3390/diagno stics14171981.
• [20]Winter H,Winski G,Busch A,et al.Targeting long noncoding RNA NUDT6 enhances smooth muscle cell survival and limits vascular disease progression[J].Mol Ther,2023,31(6):1775-1790.DOI:10.1016/j.ymthe.2023.04.020.
• [21] Yang L,Yang F,Zhao H,et al.Circular RNA circCHFR facilitates the proliferation and migration of vascular smooth muscle via miR-370/FOXO1/Cyclin D1 pathway[J].Mol Ther Nucleic Acids,2019,16:434-441.DOI:10.1016/j.omtn.2019.02.028.
• [22] Mei S,Ma X,Zhou L,et al.Circular RNA in cardiovascular diseases:biogenesis,function and application[J].Biomolecules,2024,14(8):952.DOI:10.3390/biom14080952.
• [23]Hall IF,Climent M,Quintavalle M,et al.Circ_Lrp6,a circular RNA enriched in vascular smooth muscle cells,acts as a sponge regulating miRNA-145 function[J].Circ Res,2019,124(4):498-510.DOI:10.1161/CIRCRESAHA.118.314240.
• [24]Zeng Z、Xia L,Fan S,et al.Circular RNA CircMAP3K5 acts as a MicroRNA-22-3p sponge to promote resolution of intimal hyperplasia via TET2-mediated smooth muscle cell differentiation[J].Circulation,2021,143(4):354-371.DOI:10.1161/CIRCULATIONAHA.120.049715.
• [25]Huang C,Liang D,Tatomer DC,et al.A length-dependent evolutionarily conserved pathway controls nuclear export of circular RNAs[J].Genes Dev,2018,32(9-10):639-644.DOI:10.1101/gad.314856.118.
• [26]Gori T.Restenosis after coronary stent implantation:cellular mechanisms and potential of endothelial progenitor cells(a short guide for the interventional cardiologist)[J].Cells,2022,11(13):2094.DOI:10.3390/cells11132094.
• [27]Ji R,Cheng Y,Yue J,et al.MicroRNA expression signature and antisense-mediated depletion reveal an essential role of MicroRNA in vascular neointimal lesion formation[J].Circ Res,2007,100(11):1579-1588.DOI:10.1161/CIRCRESAHA.106.141986.
• [28]Wang D,Deuse T,Stubbendorff M,et al.Local micro RNA modulation using a novel anti-miR-21-eluting stent effectively prevents experimental in-stent restenosis[J].Arterioscler Thromb Vasc Biol,2015,35(9):1945-1953.DOI:10.1161/ATVBAHA.115,305597.
• [29]Zhao H,Wen G,Huang Y,et al.MicroRNA-22 regulates smooth muscle cell differentiation from stem cells by targeting methyl CpG-binding protein 2[J].Arterioscler Thromb Vasc Biol,2015,35(4):918-929.DOI:10.1161/ATVBAHA.114.305212.
• [30]Wang J,Qian HL,Chen SY,et al.miR-22 eluting cardiovascular stent based on a self-healable spongy coating inhibits in-stent restenosis[J].Bioact Mater,2021,6(12):4686-4696.DOI:10.1016/j.bioactmat.2021.04.037.
• [31]Sun J,Marx SO,Chen HJ,et al.Role for p27(Kip1)in vascular smooth muscle cell migration[J].Circulation,2001,103(24):2967-2972.DOI:10.1161/01.cir.103.24.2967.
• [32]Santulli G,Wronska A,Uryu K,et al.A selective microRNA-based strategy inhibits restenosis while preserving endothelial function[J].J Clin Invest,2014,124(9):4102-4114.DOI:10.1172/JCI76069.
• [33]Lockhart J,Canfield J,Mong EF,et al.Nucleotidemodification alters microRNA-dependent silencing of microRNA switches[J].Mol Ther Nucleic Acids,2019,14:339-350.DOI:10.1016/j.omtn.2018.12.007.
• [34] Lockhart JH,VanWye J,Banerjee R,et al.Self-assembled miRNA-switch nanoparticles target denuded regions and prevent restenosis[J].Mol Ther,2021,29(5):1744-1757.DOI:10.1016/j.ymthe.2021.01.032.
• [35]Cheng Y,Liu X,Yang J,et al.MicroRNA-145,a novel smooth muscle cell phenotypic marker and modulator,controls vascular neointimal lesion formation[J].Circ Res,2009,105(2):158-166.DOI:10.1161/CIRCRESAHA.109.197517.
• [36]Park S,Bhang SH,La WG,et al.Dual roles of hyaluronic acids in multilayer films capturing nanocarriers for drug-eluting coatings[J].Biomaterials,2012,33(21):5468-5477.DOI:10.1016/j.biomaterials.2012.04.005.
• [37] Muthiah M,Islam MA,Cho CS,et al.Substrate-mediated delivery of microRNA-145 through a polysorbitol-based osmotically active transporter suppresses smooth muscle cell proliferation:implications for restenosis treatment[J].J Biomed Nanotechnol,2014,10(4):571-579.DOI:10.1166/jbn.2014.1737.
• [38]Son S,Jang J,Youn H,et al.A brain-targeted rabies virus glycoprotein-disulfide linked PEI nanocarrier for delivery of neurogenic microRNA[J].Biomaterials,20 11,32(21):4968-4975.DOI:10.1016/j.biomaterials.2011.03.047.
• [39]Che HL,Bae IH,Lim KS,et al.Novel fabrication of microRNA nanoparticle-coated coronary stent for prevention of post-angioplasty restenosis[J].Korean Circ J,2016,46(1):23-32.DOI:10.4070/kcj.2016.46.1.23.
• [40]Duguay D,deBlois D.Differential regulation of Akt,caspases and MAP kinases underlies smooth muscle cell apoptosis during aortic remodelling in SHR treated with amlodipine[J].Br J Pharmacol,2007,151(8):1315-1323.DOI:10.1038/sj.bjp.0707334.
• [41]Che HL,Bae IH,Lim KS,et al.Therapeutic effect of Akt1 siRNA nanoparticle eluting coronary stent on suppression of post-angioplasty restenosis[J].J Biomed Nanotechnol,2016,12(6):1211-1222.DOI:10.1166/jbn.2016.2255.
• [42]Boulberdaa M,Scott E,Ballantyne M,et al.A role for the long noncoding RNA SENCR in commitment and function of endothelial cells[J].Mol Ther,2016,24(5):978-990.DOI:10.1038/mt.2016.41.
• [43]Hetherington I,Totary-Jain H.Anti-atherosclerotic therapies:milestones,challenges,and emerging innovations[J].Mol Ther,2022,30(10):3106-3117.DOI:10.1016/j.ymthe.2022.08.024.
• [44]Brown SD,Klimi E,Bakker WAN,et al.Non-coding RNAs to treat vascular smooth muscle cell dysfunction[J].Br J Pharmacol,2025,182(2):246-280.DOI:10.1111/bph.16409.
• [45]Lekshmi KM,Che HL,Cho CS,et al.Drug-and gene-eluting stents for preventing coronary restenosis[J].Chonnam Med J,2017,53(1):14-27.DOI:10.4068/cmj.2017.53.1.14.
• [46]Duan X,Yang Y,Zhang T,et al.Research progress of metal biomaterials with potential applications as cardiovascular stents and their surface treatment methods to improve biocompatibility[J].Heliyon,2024,10(4):e25515.DOI:10.1016/j.heliyon.2024.e25 515.